909849-96-3 Usage
Description
Montelukast Sulfoxide (Mixture of diastereomers) is a metabolite of Montelukast, which is a pharmaceutical compound used for treating various respiratory conditions. It is a light yellow solid and consists of a mixture of diastereomers, which are stereoisomers that are not mirror images of each other.
Uses
Used in Pharmaceutical Industry:
Montelukast Sulfoxide (Mixture of diastereomers) is used as an impurity in the synthesis and manufacturing process of Montelukast. It is also known as Montelukast EP Impurity C, Montelukast USP Related Compound A, and Montelukast Sulfoxid. The presence of this metabolite is essential for the quality control and standardization of Montelukast products, ensuring their safety and efficacy in treating respiratory conditions such as asthma and allergic rhinitis.
Check Digit Verification of cas no
The CAS Registry Mumber 909849-96-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,9,8,4 and 9 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 909849-96:
(8*9)+(7*0)+(6*9)+(5*8)+(4*4)+(3*9)+(2*9)+(1*6)=233
233 % 10 = 3
So 909849-96-3 is a valid CAS Registry Number.
InChI:InChI=1/C35H36ClNO4S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(42(41)23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+
909849-96-3Relevant articles and documents
Identification, synthesis and characterization of impurities of Montelukast sodium
Sunil Kumar,Anjaneyulu,Hima Bindu
scheme or table, p. 4536 - 4546 (2012/02/04)
Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.
SPECIFIC IMPURITIES OF MONTELUKAST
-
Page/Page column 23-24, (2009/10/22)
The subject-matter of the invention consists in a method of removing specific impurities of montelukast of formula (I), which occur due to chemical instability of the target substance and also contaminate the substance in the preparation process. Further, methods of isolation of specific impurities of montelukast defined by formulae (V-A), (IV-A), (XIIIa-A), (XIIIb-A) and analytic methods used for the control of the production of montelukast in the pharmaceutical quality.